Imaging agent scans in advanced bladder, breast and lung cancers
Tests an imaging agent in adults with advanced urothelial, breast or lung cancer.
Plain-language title generated from the registry record
Registry title: Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Key facts
- Where
- Nedlands, Perth, and St Leonards, AustraliaSee the 3 sites
- Phase
- Early phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic urothelial cancer, hormone receptor-positive HER2-negative breast cancer, triple-negative breast cancer, or non-small-cell lung cancer. It tests an imaging agent.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Metastatic urothelial cancer, HR+ and HER2- breast cancer, triple-negative breast cancer, or non-small-cell lung cancer, proven by biopsy.
Main reasons for not taking part
- Women who can have children and are pregnant or breastfeeding
Read by machine on 9 November 2026.
Where in Australia
- NedlandsNedlands, AustraliaTaking people
- PerthPerth, AustraliaTaking people
- St LeonardsSt Leonards, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RayzeBio, Inc.
- Trial code
- NCT07671092
- Record updated
- 13 October 2026
- Original description
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.Read full original descriptionShow less
A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Inclusion: Are at least 18 years old at the time of signing the informed consent form (ICF); Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
Exclusion: For Women of Childbearing Potential: Are pregnant or breastfeeding; Note: Additional criteria may apply and will be assessed by the study site.